Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14039391 | 0.92 | ALDH1A1 (0.51) | ALDH1A1CA1CA2MMP1MMP2 | |
| SCHEMBL10282879 | 0.86 | ALDH1A1 (0.56) | ALDH1A1CA1CA2MMP1MMP2 | |
| SCHEMBL12858598 | 0.84 | TSHR (0.55) | ALDH1A1CA1CA2MMP1MMP2 | |
| SCHEMBL12284487 | 0.84 | ALDH1A1 (0.56) | ALDH1A1CA1CA2MMP1MMP2 | |
| SCHEMBL7189479 | 0.84 | CYP2C19 (0.50) | ALDH1A1CA1CA2MMP1MMP2 | |
| SCHEMBL12646339 | 0.81 | GHSR (0.44) | ALDH1A1CA1CA2GAASMN1; SMN2 | |
| SCHEMBL12169312 | 0.79 | ALDH1A1 (0.51) | ALDH1A1CA1CA2MMP1MMP2 | |
| SCHEMBL634085 | 0.79 | ALDH1A1 (0.79) | ALDH1A1CA1CA2MMP1MMP2 | |
| SCHEMBL21510335 | 0.78 | MEP1B (0.52) | ALDH1A1GAASMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL3197980 | 0.77 | TSHR (0.55) | ALDH1A1CA1CA2MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119490437-A | Chiral amino alcohol compound containing carbamate structure and preparation method thereof | 浙江工业大学 | 2025-02-21 | — | — | CN | disclosed |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | GONGWIN BIOPHARM CO., LTD (TW) | 2023-10-12 | — | — | US | disclosed |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| US-11752118-B2 | Method for treating melanoma | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| US-20220168248-A1 | METHOD FOR TREATING MELANOMA | GONGWIN BIOPHARM CO., LTD (TW) | 2022-06-02 | — | — | US | disclosed |
| US-20200338028-A1 | BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR MODULATING LIPID RAFT | GONGWIN BIOPHARM CO., LTD. (TW) | 2020-10-29 | — | — | US | disclosed |
| US-10548862-B2 | Topical formulation and method for preventing or treating acne | Wu, Lester J. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190321313-A1 | BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR TREATING CANCER | Gongwin Biopharm Holdings Co., Ltd. | 2019-10-24 | — | — | US | disclosed |
| US-20190201356-A1 | TOPICAL FORMULATION AND METHOD FOR PREVENTING OR TREATING ACNE | GONGWIN BIOPHARM CO., LTD. (TW) | 2019-07-04 | — | — | US | disclosed |
| US-9782370-B2 | Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma | Gongwin Biopharm Holdings Co., Ltd. (KY) | 2017-10-10 | — | — | US | disclosed |
| US-7973038-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-05 | — | — | US | disclosed |
| US-7956052-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-07 | — | — | US | disclosed |
| US-20100210638-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-19 | — | — | US | disclosed |
| US-7741321-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-22 | — | — | US | disclosed |
| US-20100087435-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-7659268-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090143381-A1 | MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-06-04 | — | — | US | disclosed |
| US-20080306062-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087435-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 1786/4885CA1 4884/4885CA2 2789/4885 |
| US-20190321313-A1 | BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR TREATING CANCER | ARSA, ABCB1, ABCG2 | ALDH1A1 689/4885CA1 3523/4885CA2 2038/4885 |
| US-10548862-B2 | Topical formulation and method for preventing or treating acne | CUTA, STS, ALAD | ALDH1A1 669/4885CA1 4860/4885CA2 4374/4885 |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | LIPE, FABP4, LIPA | ALDH1A1 728/4885CA1 4568/4885CA2 4175/4885 |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | ALDH1A1 3710/4885CA1 4882/4885CA2 3603/4885 |
| US-20220168248-A1 | METHOD FOR TREATING MELANOMA | TYR, MITF, BRAF | ALDH1A1 528/4885CA1 3299/4885CA2 1053/4885 |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | TP53, MCL1, TOP2B | ALDH1A1 381/4885CA1 1345/4885CA2 989/4885 |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | ALDH1A1 1786/4885CA1 4884/4885CA2 2789/4885 |
| US-20100210638-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 1786/4885CA1 4884/4885CA2 2789/4885 |
| US-11752118-B2 | Method for treating melanoma | TYR, MITF, BRAF | ALDH1A1 528/4885CA1 3299/4885CA2 1053/4885 |
| US-20080306062-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 1786/4885CA1 4884/4885CA2 2789/4885 |
| US-20090143381-A1 | MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 1985/4885CA1 4884/4885CA2 2553/4885 |
| US-20200338028-A1 | BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR MODULATING LIPID RAFT | ABCB4, SPTSSB, SMPD2 | ALDH1A1 1604/4885CA1 4503/4885CA2 4026/4885 |
| US-20190201356-A1 | TOPICAL FORMULATION AND METHOD FOR PREVENTING OR TREATING ACNE | CUTA, STS, ALAD | ALDH1A1 669/4885CA1 4860/4885CA2 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.